AR074184A1 - Compuestos de 7-azaspiro[3.5]nonano-7-carboxamida, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de afecciones mediadas por la inhibicion de faah - Google Patents
Compuestos de 7-azaspiro[3.5]nonano-7-carboxamida, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de afecciones mediadas por la inhibicion de faahInfo
- Publication number
- AR074184A1 AR074184A1 ARP090104209A ARP090104209A AR074184A1 AR 074184 A1 AR074184 A1 AR 074184A1 AR P090104209 A ARP090104209 A AR P090104209A AR P090104209 A ARP090104209 A AR P090104209A AR 074184 A1 AR074184 A1 AR 074184A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- haloalkyl
- optionally substituted
- haloalkoxy
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102100027297 Fatty acid 2-hydroxylase Human genes 0.000 title 1
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 title 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 7
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 abstract 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 3
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010058019 Cancer Pain Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000001640 Fibromyalgia Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001294 Nociceptive Pain Diseases 0.000 abstract 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 208000035868 Vascular inflammations Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 201000009961 allergic asthma Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- AXLOCHLTNQDFFS-BESJYZOMSA-N azastene Chemical group C([C@H]1[C@@H]2CC[C@@]([C@]2(CC[C@@H]1[C@@]1(C)C2)C)(O)C)C=C1C(C)(C)C1=C2C=NO1 AXLOCHLTNQDFFS-BESJYZOMSA-N 0.000 abstract 1
- 208000029028 brain injury Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 150000004867 thiadiazoles Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
Abstract
Se proporcionan compuestos de 7-azaspiro[3.5]nonano-7-carboxamida y las sales farmacéuticamente aceptables de tales compuestos utiles en el tratamiento de enfermedades o afecciones asociadas a la actividad de hidrolasa de amidas de ácidos grasos (FAAH), incluyendo las afecciones dolor agudo, dolor cronico, dolor neuropático, dolor nociceptivo, dolor inflamatorio, cáncer y dolor del cáncer, fibromialgia, artritis reumatoide, enfermedad inflamatoria del intestino, lupus, diabetes, asma alérgica, inflamacion vascular, incontinencia urinaria, hiperactividad vesical, emesis, trastornos cognitivos, ansiedad, depresion, trastornos del sueno, trastornos de la alimentacion, trastornos del movimiento, glaucoma, psoriasis, esclerosis multiple, trastornos cerebrovasculares, lesion cerebral, trastornos gastrointestinales, hipertension o enfermedad cardiovascular. Reivindicacion 1: Un compuesto caracterizado porque es de formula (1), en el que: Ar1 se selecciona entre: los compuesto a) a e) del grupo de formulas (2); f) benzoisoxazol opcionalmente sustituido por de 1 a 3 sustituyentes seleccionados entre halo, alquilo C1-3, alcoxi C1-3, haloalquilo C1-3 o haloalcoxi C1-3; o g) piridina, piridazina, pirimidina, o pirazina; en los que la piridina, piridazina, pirimidina o pirazina se sustituye opcionalmente por de 1 a 3 sustituyentes halo, alquilo C1-3, -(CH2)n-(cicloalquilo C3-6), alcoxi C1-3, haloalquilo C1-3 o haloalcoxi C1-3; Ar2 se selecciona entre: a) fenilo opcionalmente sustituido por de 1 a 5 sustituyentes seleccionados entre halo, alquilo C1-6, -(CH2)n-(cicloalquilo C3-6), alcoxi C1-6, -(CH2)n(cicloalcoxi C3-6), haloalquilo C1-6, haloalcoxi C1-6, -O-CH2-CH2-O-(alquilo C1-6), o -O-CH2-CH2-O-(haloalquilo C1-6); en los que el fenilo se sustituye opcionalmente por un sustituyente de las formulas -R9, -O-R9, -O-(CH2)p-R9, o -(CH2)p-O-R9; b) oxazol, isoxazol, tiazol, isotiazol, oxadiazol o tiadiazol sustituido por un sustituyente de las formulas -(CH2)n-R9, -(CH2)m-O-R9, o -(CH2)p-O-(CH2)p-R9; c) un heterociclo de la formula (3), en el que X es CH2 o O, y W es (CH2)m o CF2; o d) naftilo, quinolinilo o isoquinolinilo opcionalmente sustituido por de 1 a 3 sustituyentes halo, alquilo C1-3, alcoxi C1-3, haloalquilo C1-3 o haloalcoxi C1-3; en los que si Ar1 es piridina, piridazina, pirimidina, o pirazina, entonces Ar2 debe ser un anillo de fenilo sustituido por -O-R9; R1 y R2 se seleccionan independientemente entre hidrogeno, F o CH3; R3 es hidrogeno, CH3, -O-CH3, OH, CN o F; R4 es hidrogeno, alquilo C1-6, -(CH2)n-(cicloalquilo C3-6) o haloalquilo C1-6; R5 es alquilo C1-3; R6 es hidrogeno, alquilo C1-6 o haloalquilo C1-3; R7 es alquilo C1-3, -(CH2)n-(cicloalquilo C3-6), R9 o -CH2-O-R9; R8 es fenilo opcionalmente sustituido por entre 1 y 3 sustituyentes seleccionados entre los grupos halo, alquilo C1-3, alcoxi C1-3, haloalquilo C1-3 o haloalcoxi C1-3; R9 se selecciona entre fenilo, naftilo o heteroarilo; en el que R9 se sustituye opcionalmente por entre 1 y 3 sustituyentes seleccionados entre halo, alquilo C1-3, -(CH2)n-(cicloalquilo C3-6), alcoxi C1-3, -(CH2)n-(cicloalcoxi C3-6), haloalquilo C1-3, o haloalcoxi C1-3; m es 1, 2 o 3; n es 0, 1, 2, 3 o 4; y p es 1 o 2; o su sal farmacéuticamente aceptable.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10971208P | 2008-10-30 | 2008-10-30 | |
| US12134908P | 2008-12-10 | 2008-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074184A1 true AR074184A1 (es) | 2010-12-29 |
Family
ID=41560876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104209A AR074184A1 (es) | 2008-10-30 | 2009-10-30 | Compuestos de 7-azaspiro[3.5]nonano-7-carboxamida, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de afecciones mediadas por la inhibicion de faah |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100113465A1 (es) |
| EP (1) | EP2358704A1 (es) |
| JP (1) | JP2012507500A (es) |
| AR (1) | AR074184A1 (es) |
| CA (1) | CA2738776A1 (es) |
| TW (1) | TW201022257A (es) |
| UY (1) | UY32205A (es) |
| WO (1) | WO2010049841A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100130477A1 (en) * | 2008-11-25 | 2010-05-27 | Astrazeneca Ab | Spirocyclobutyl Piperidine Derivatives |
| FR2941696B1 (fr) * | 2009-02-05 | 2011-04-15 | Sanofi Aventis | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| US20130029978A1 (en) | 2009-12-25 | 2013-01-31 | Mochida Pharmaceutical Co., Ltd. | Novel aryl urea derivative |
| US20130150346A1 (en) | 2010-01-08 | 2013-06-13 | Quest Ventures Ltd. | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome |
| WO2011123719A2 (en) | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating abdominal, visceral and pelvic pain |
| SG11201405056UA (en) | 2012-03-02 | 2014-09-26 | Genentech Inc | Amido spirocyclic amide and sulfonamide derivatives |
| WO2014054053A1 (en) * | 2012-10-03 | 2014-04-10 | Advinus Therapeutics Limited | Spirocyclic compounds, compositions and medicinal applications thereof |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| CN104059041B (zh) * | 2013-03-20 | 2018-10-16 | 上海方楠生物科技有限公司 | 抗糖尿病药物达格列净中间体的制备方法 |
| US10414733B2 (en) | 2014-07-31 | 2019-09-17 | Basf Se | Process for preparing pyrazoles |
| WO2016180833A1 (en) | 2015-05-11 | 2016-11-17 | Basf Se | Process for preparing 4-amino-pyridazines |
| WO2018082964A1 (en) | 2016-11-04 | 2018-05-11 | Basf Se | Process for the production of pyridazinyl-amides in a one-pot synthesis |
| WO2019040404A1 (en) * | 2017-08-21 | 2019-02-28 | Microbiotix, Inc. | METABOLIC-STABLE METABOLIC-N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS |
| WO2020077071A1 (en) * | 2018-10-10 | 2020-04-16 | Forma Therapeutics, Inc. | Inhibiting fatty acid synthase (fasn) |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| UY39516A (es) * | 2020-11-13 | 2022-05-31 | H Lundbeck As | Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200633990A (en) * | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| SI2937341T1 (sl) * | 2004-12-30 | 2017-10-30 | Janssen Pharmaceutica N.V. | Fenilamidni derivati 4-(benzil)-piperazin-1-karboksilne kisline in z njimi povezane spojine kot modulatorji hidrolaze amidov maščobnih kislin (FAAH) za zdravljenje anksioznosti, bolečine in drugih stanj |
| TWI363161B (en) * | 2006-07-26 | 2012-05-01 | Ind Tech Res Inst | Light emitting diode lighting module with improved heat dissipation structure |
-
2009
- 2009-10-06 US US12/573,897 patent/US20100113465A1/en not_active Abandoned
- 2009-10-16 EP EP09744463A patent/EP2358704A1/en not_active Withdrawn
- 2009-10-16 JP JP2011533860A patent/JP2012507500A/ja not_active Withdrawn
- 2009-10-16 WO PCT/IB2009/054560 patent/WO2010049841A1/en not_active Ceased
- 2009-10-16 CA CA2738776A patent/CA2738776A1/en not_active Abandoned
- 2009-10-28 UY UY0001032205A patent/UY32205A/es not_active Application Discontinuation
- 2009-10-29 TW TW098136734A patent/TW201022257A/zh unknown
- 2009-10-30 AR ARP090104209A patent/AR074184A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UY32205A (es) | 2010-05-31 |
| EP2358704A1 (en) | 2011-08-24 |
| JP2012507500A (ja) | 2012-03-29 |
| CA2738776A1 (en) | 2010-05-06 |
| WO2010049841A1 (en) | 2010-05-06 |
| TW201022257A (en) | 2010-06-16 |
| US20100113465A1 (en) | 2010-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074184A1 (es) | Compuestos de 7-azaspiro[3.5]nonano-7-carboxamida, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de afecciones mediadas por la inhibicion de faah | |
| JP6630771B2 (ja) | Ｍｅｋインヒビターとしてのヘテロシクリル化合物 | |
| AU2008318491B2 (en) | Cytokine inhibitors | |
| TWI548616B (zh) | 巨大戟萜醇－３－醯化物iii及巨大戟萜醇－３－胺基甲酸酯化物 | |
| TWI538905B (zh) | 雙環［３．２．１］辛基醯胺衍生物及其用途 | |
| AR059895A1 (es) | Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos | |
| HRP20170695T1 (hr) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka | |
| RU2009142431A (ru) | Производные триазолопиридинкарбоксамидов и триазолопиримидинкарбоксамидов, их получение и их применение в терапии | |
| WO2009127944A8 (en) | Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors | |
| AR069545A1 (es) | Derivados de aril y heteroarilcarbonilo de benzomorfanos y estructuras relacionadas, composiciones farmaceuticas que contienen dichos compuestos, obtencion de las mismas, su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa (hsd) 1 y | |
| AR071719A1 (es) | Derivados aliciclicos de acido carboxilico de benzomorfanos y estructuras relacionadas, medicamentos que contienen dichos compuestos y su uso.procesos de obtencion | |
| AR063331A1 (es) | Derivados de biaril eter urea y composiciones farmaceuticas | |
| RU2010149611A (ru) | Ациламинозамещенные производные конденсированных циклопентанкарбоновых кислот и их применение в качестве фармацевтических средств | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| CO6251251A2 (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
| MX2010009658A (es) | Derivados de azetidina. | |
| BRPI0719861A2 (pt) | Compostos heteroaromáticos bicíclicos | |
| TW201938166A (zh) | 帽依賴性核酸內切酶抑制劑 | |
| AR072353A1 (es) | Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como modula-dores de leucotrieno a4 hidrolasa | |
| AR051290A1 (es) | Derivados de hidantoina sustituidas | |
| AR075951A1 (es) | Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek | |
| JP7017787B2 (ja) | ユビキチン化－プロテアソーム系に関連する化合物および薬学的組成物 | |
| EP2566481A1 (en) | Aza-indole derivatives useful as modulators of faah | |
| AR051802A1 (es) | Heterociclos antagonistas de mchr1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |